-
EP3714937
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP3714937
| EP3714937 - DETERMINING HEMATOLOGIC TOXICITY RISK FOLLOWING RADIOTHERAPY [Right-click to bookmark this link] | Status | The application is deemed to be withdrawn Status updated on 06.08.2021 Database last updated on 12.07.2024 | |
| Former | The application has been published Status updated on 28.08.2020 | Most recent event Tooltip | 06.08.2021 | Application deemed to be withdrawn | published on 08.09.2021 [2021/36] | Applicant(s) | For all designated states Koninklijke Philips N.V. High Tech Campus 52 5656 AG Eindhoven / NL | [2020/40] | Inventor(s) | 01 /
DA SILVA RODRIGUES, Pedro Jorge c/o Philips International B.V. - Intellectual Property & Standards High Tech Campus 5 5656 AE Eindhoven / NL | 02 /
BONDAR, Maria Luiza c/o Philips International B.V. - Intellectual Property & Standards High Tech Campus 5 5656 AE Eindhoven / NL | 03 /
VITTORINO DE ALMEIDA, Vanda Lucia de c/o Philips International B.V. - Intellectual Property & Standards High Tech Campus 5 5656 AE Eindhoven / NL | [2020/40] | Representative(s) | de Haan, Poul Erik, et al Philips International B.V. Philips Intellectual Property & Standards High Tech Campus 5 5656 AE Eindhoven / NL | [2020/40] | Application number, filing date | 19165769.1 | 28.03.2019 | [2020/40] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | EP3714937 | Date: | 30.09.2020 | Language: | EN | [2020/40] | Search report(s) | (Supplementary) European search report - dispatched on: | EP | 25.09.2019 | Classification | IPC: | A61N5/10 | [2020/40] | CPC: |
A61N5/1071 (EP,US);
A61N5/1031 (EP,US);
G16H20/40 (US)
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2020/40] | Extension states | BA | Not yet paid | ME | Not yet paid | Validation states | KH | Not yet paid | MA | Not yet paid | MD | Not yet paid | TN | Not yet paid | Title | German: | BESTIMMUNG DES RISIKOS EINER HÄMATOLOGISCHEN TOXIZITÄT NACH EINER STRAHLENTHERAPIE | [2020/40] | English: | DETERMINING HEMATOLOGIC TOXICITY RISK FOLLOWING RADIOTHERAPY | [2020/40] | French: | DÉTERMINATION DU RISQUE DE TOXICITÉ HÉMATOLOGIQUES SUITE À UNE RADIOTHÉRAPIE | [2020/40] | Examination procedure | 31.03.2021 | Application deemed to be withdrawn, date of legal effect [2021/36] | 22.04.2021 | Despatch of communication that the application is deemed to be withdrawn, reason: examination fee not paid in time [2021/36] | Fees paid | Penalty fee | Additional fee for renewal fee | 31.03.2021 | 03 M06 Not yet paid |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Documents cited: | Search | [A]WO0110461 (IDEC PHARMA CORP [US], et al) [A] 1-17 * claim 1 *; | [IA]WO2015116932 (UNIV JOHNS HOPKINS [US]) [I] 1,3-6,11-13 * figures 1,2,6; claims 1,3 * [A] 2,7-10,14,15; | [A]US9925393 (NAKATSUGAWA MINORU [US], et al) [A] 1-17* figures 3,9,14 * | by applicant | - YAZDI et al., "Standard radiotherapy but not chemotherapy impairs systemic immunity in non-small cell lung cancer", Oncoimmunology, (20160000), vol. 5, no. 12, page e1255393 | - SHAHID et al., "Review of hematological indices of cancer patients receiving combined chemotherapy & radiotherapy or receiving radiotherapy alone", Critical Reviews in Oncology/Hematology, (20160000), vol. 105, doi:doi:10.1016/j.critrevonc.2016.06.001, pages 145 - 155, XP029672666 DOI: http://dx.doi.org/10.1016/j.critrevonc.2016.06.001 | - HO et al., "Association between pretreatment lymphocyte count and response to PD 1 inhibitors in head and neck squamous cell carcinomas", Journal for ImmunoTherapy of Cancer, (20180000), vol. 6, page 84 | - DIEHL et al., "Relationships between lymphocyte counts and treatment-related toxicities and clinical responses in patients with solid tumors treated with PD-1 checkpoint inhibitors", Oncotarget, (20170000), vol. 8, no. 69, pages 114268 - 114280 | - JABBOUR et al., "Integrating immunotherapy into chemoradiation regimens for medically inoperable locally advanced non-small cell lung cancer", Transl. Lung Cancer Res., (20170400), vol. 6, no. 2, pages 113 - 118 | - ANTONIA SJ; VILLEGAS A; DANIEL D et al., "Durvalumab after chemoradiotherapy in stage III non-small cell lung cancer", N Engl J Med, (20170000), vol. 377, pages 1919 - 29 | - RIZVI; PETERS, "Immunotherapy for Unresectable Stage III Non-Small-Cell Lung Cancer", N Engl J Med, (20171116), vol. 377, page 20 | - DEEK et al., "Thoracic Vertebral Body Irradiation Contributes to Acute Hematologic Toxicity During Chemoradiation Therapy for Non-Small Cell Lung Cancer", Int J Radiat Oncol Biol Phys., (20160101), vol. 94, no. 1, doi:doi:10.1016/j.ijrobp.2015.09.022, pages 147 - 154, XP029348440 DOI: http://dx.doi.org/10.1016/j.ijrobp.2015.09.022 | - "Emerging Therapies for Stage III Non-Small Cell Lung Cancer: Stereotactic Body Radiation Therapy and Immunotherapy", Front Oncol., (20170904), vol. 7, page 197 | - KUTCHER G J; BURMAN C, "Calculation of complication probability factors for non-uniform normal tissue irradiation: the effective volume method", Int. J. Radiat. Oncol. Biol. Phys., (19890000), vol. 16, pages 1623 - 30, XP026845889 | - I. EL NAQA et al., "Dose response explorer: an integrated open-source tool for exploring and modelling radiotherapy dose-volume outcome relationships", Phys. Med. Biol., (20061100), vol. 51, no. 22, doi:doi:10.1088/0031-9155/51/22/001, pages 5719 - 5735, XP020096031 DOI: http://dx.doi.org/10.1088/0031-9155/51/22/001 | - I. EL NAQA, "Dose response explorer: an integrated open-source tool for exploring and modelling radiotherapy dose-volume outcome relationships", Phys. Med. Biol., (20061100), vol. 51, no. 22, doi:doi:10.1088/0031-9155/51/22/001, pages 5719 - 5735, XP020096031 DOI: http://dx.doi.org/10.1088/0031-9155/51/22/001 | - ROSSI L; BIJMAN R; SCHILLEMANS W; ALUWINI S; CAVEDON C; WITTE M; INCROCCI L; HEIJMEN B, "Texture analysis of 3D dose distributions for predictive modelling of toxicity rates in radiotherapy", Radiother Oncol., (20181200), vol. 129, no. 3, doi:doi:10.1016/j.radonc.2018.07.027, pages 548 - 553, XP085549888 DOI: http://dx.doi.org/10.1016/j.radonc.2018.07.027 | - BARNEY et al., "Radiation Dose to the Thoracic Vertebral Bodies Is Associated With Acute Hematologic Toxicities in Patients Receiving Concurrent Chemoradiation for Lung Cancer: Results of a Single-Center Retrospective Analysis", Int J Radiation Oncol Biol Phys, (20180000), vol. 100, no. 3, page 748e755 | - SEMENENKO; LI, "Lyman-Kutcher-Burman NTCP model parameters for radiation pneumonitis and xerostomia based on combined analysis of published clinical data", Phys Med Biol., (20080207), vol. 53, no. 3, pages 737 - 55, XP020127356 | - TSOUGOS et al., "Clinical validation of the LKB model and parameter sets for predicting radiation-induced pneumonitis from breast cancer radiotherapy", Phys. Med. Biol., (20060000), vol. 51, doi:doi:10.1088/0031-9155/51/3/L01, page L1, XP020096130 DOI: http://dx.doi.org/10.1088/0031-9155/51/3/L01 |